Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus-Clinical Practice Position Statement of the Polish Society of Nephrology.

Moreover, the perindopril and indapamide treatment showed the nephroprotective efficacy: 21% reduction in all renal events (95% CI 15–27%, p < 0.0001), with a borderline significant reduction in new onset or worsening nephropathy (development of albuminuria, doubling of S cr to at least 200 μmol/L, need for renal replacement therapy, or death due to renal disease) 3.3% vs. 3.9% (relative risk reduction 18% [–1 to 32%], p = 0.055) and a significant reduction in the development of albuminuria (19.6% vs. 23.6%; 21% [14–27%]; p < 0.0001) [ 153 ].

also in 11,409 other papers

placebo were highly significant).

also in 132,142 other papers